vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $15.1M, roughly 1.5× Aterian, Inc.). Aterian, Inc. runs the higher net margin — -52.5% vs -416.2%, a 363.6% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -38.5%). Aterian, Inc. produced more free cash flow last quarter ($-1.0M vs $-69.4M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -13.5%).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ATER vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $23.0M |
| Net Profit | $-7.9M | $-95.8M |
| Gross Margin | 56.1% | — |
| Operating Margin | -51.1% | -428.9% |
| Net Margin | -52.5% | -416.2% |
| Revenue YoY | -38.5% | 78.8% |
| Net Profit YoY | -512.2% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | $23.0M | ||
| Q3 25 | $19.0M | $13.8M | ||
| Q2 25 | $19.5M | $14.2M | ||
| Q1 25 | $15.4M | $16.6M | ||
| Q4 24 | $24.6M | $12.9M | ||
| Q3 24 | $26.2M | $9.1M | ||
| Q2 24 | $28.0M | $7.0M | ||
| Q1 24 | $20.2M | $28.9M |
| Q4 25 | $-7.9M | $-95.8M | ||
| Q3 25 | $-2.3M | $-101.3M | ||
| Q2 25 | $-4.9M | $-101.3M | ||
| Q1 25 | $-3.9M | $-114.3M | ||
| Q4 24 | $-1.3M | $-128.9M | ||
| Q3 24 | $-1.8M | $-135.7M | ||
| Q2 24 | $-3.6M | $-147.0M | ||
| Q1 24 | $-5.2M | $-107.4M |
| Q4 25 | 56.1% | — | ||
| Q3 25 | 56.1% | — | ||
| Q2 25 | 54.3% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 63.4% | — | ||
| Q3 24 | 60.3% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 65.1% | — |
| Q4 25 | -51.1% | -428.9% | ||
| Q3 25 | -10.7% | -808.9% | ||
| Q2 25 | -23.1% | -772.2% | ||
| Q1 25 | -24.1% | -726.6% | ||
| Q4 24 | -6.5% | -1059.9% | ||
| Q3 24 | -6.6% | -1589.0% | ||
| Q2 24 | -11.5% | -1998.6% | ||
| Q1 24 | -26.1% | -394.0% |
| Q4 25 | -52.5% | -416.2% | ||
| Q3 25 | -12.0% | -735.2% | ||
| Q2 25 | -25.0% | -710.8% | ||
| Q1 25 | -25.4% | -687.6% | ||
| Q4 24 | -5.3% | -1001.2% | ||
| Q3 24 | -6.8% | -1489.5% | ||
| Q2 24 | -13.0% | -2112.6% | ||
| Q1 24 | -25.5% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | — | $-1.34 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $671.4M |
| Total Assets | $29.6M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $449.9M | ||
| Q3 25 | $7.6M | $511.0M | ||
| Q2 25 | $10.5M | $459.7M | ||
| Q1 25 | $14.3M | $503.7M | ||
| Q4 24 | $18.0M | $601.5M | ||
| Q3 24 | $16.1M | $658.1M | ||
| Q2 24 | $20.3M | $691.1M | ||
| Q1 24 | $17.5M | $791.3M |
| Q4 25 | $15.2M | $671.4M | ||
| Q3 25 | $22.6M | $748.4M | ||
| Q2 25 | $24.3M | $715.3M | ||
| Q1 25 | $27.0M | $779.9M | ||
| Q4 24 | $30.0M | $872.0M | ||
| Q3 24 | $30.6M | $962.6M | ||
| Q2 24 | $30.9M | $971.1M | ||
| Q1 24 | $33.0M | $1.0B |
| Q4 25 | $29.6M | $842.1M | ||
| Q3 25 | $40.1M | $925.3M | ||
| Q2 25 | $45.4M | $898.9M | ||
| Q1 25 | $49.8M | $986.2M | ||
| Q4 24 | $49.5M | $1.2B | ||
| Q3 24 | $52.1M | $1.2B | ||
| Q2 24 | $59.9M | $1.2B | ||
| Q1 24 | $55.7M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-69.3M |
| Free Cash FlowOCF − Capex | $-1.0M | $-69.4M |
| FCF MarginFCF / Revenue | -6.9% | -301.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | $-69.3M | ||
| Q3 25 | $-1.6M | $-76.9M | ||
| Q2 25 | $-4.4M | $-99.6M | ||
| Q1 25 | $-3.9M | $-148.9M | ||
| Q4 24 | $-9.0K | $-85.2M | ||
| Q3 24 | $-722.0K | $-84.8M | ||
| Q2 24 | $2.9M | $-58.2M | ||
| Q1 24 | $-6.0K | $-120.7M |
| Q4 25 | $-1.0M | $-69.4M | ||
| Q3 25 | $-1.6M | $-76.9M | ||
| Q2 25 | $-4.4M | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | $2.9M | $-59.2M | ||
| Q1 24 | $-42.0K | $-123.2M |
| Q4 25 | -6.9% | -301.6% | ||
| Q3 25 | -8.4% | -558.2% | ||
| Q2 25 | -22.7% | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | 10.3% | -850.9% | ||
| Q1 24 | -0.2% | -425.7% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.2% | 0.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 4.4% | ||
| Q4 24 | 0.0% | 7.6% | ||
| Q3 24 | 0.0% | 14.0% | ||
| Q2 24 | 0.0% | 14.5% | ||
| Q1 24 | 0.2% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
